MA55097A - Oxystérols et leurs procédés d'utilisation - Google Patents
Oxystérols et leurs procédés d'utilisationInfo
- Publication number
- MA55097A MA55097A MA055097A MA55097A MA55097A MA 55097 A MA55097 A MA 55097A MA 055097 A MA055097 A MA 055097A MA 55097 A MA55097 A MA 55097A MA 55097 A MA55097 A MA 55097A
- Authority
- MA
- Morocco
- Prior art keywords
- oxysterols
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189048P | 2015-07-06 | 2015-07-06 | |
| US201662280394P | 2016-01-19 | 2016-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55097A true MA55097A (fr) | 2022-01-05 |
Family
ID=57686105
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055097A MA55097A (fr) | 2015-07-06 | 2016-07-06 | Oxystérols et leurs procédés d'utilisation |
| MA42410A MA42410B1 (fr) | 2015-07-06 | 2016-07-06 | Oxystérols et leurs méthodes d'utilisation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42410A MA42410B1 (fr) | 2015-07-06 | 2016-07-06 | Oxystérols et leurs méthodes d'utilisation |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10201550B2 (fr) |
| EP (2) | EP3828194A1 (fr) |
| JP (3) | JP2018519351A (fr) |
| KR (2) | KR102703602B1 (fr) |
| CN (2) | CN113292623A (fr) |
| AU (3) | AU2016289967B2 (fr) |
| BR (3) | BR122023021450A2 (fr) |
| CA (1) | CA2991214C (fr) |
| CO (1) | CO2018000660A2 (fr) |
| CY (1) | CY1124496T1 (fr) |
| DK (1) | DK3319611T3 (fr) |
| ES (1) | ES2865258T3 (fr) |
| HR (1) | HRP20210526T8 (fr) |
| HU (1) | HUE053778T2 (fr) |
| IL (2) | IL256710B2 (fr) |
| LT (1) | LT3319611T (fr) |
| MA (2) | MA55097A (fr) |
| MD (1) | MD3319611T2 (fr) |
| MX (2) | MX2018000282A (fr) |
| PE (1) | PE20180483A1 (fr) |
| PH (1) | PH12018500065A1 (fr) |
| PL (1) | PL3319611T3 (fr) |
| PT (1) | PT3319611T (fr) |
| RS (1) | RS61718B1 (fr) |
| RU (2) | RU2021100620A (fr) |
| SG (1) | SG10202010553XA (fr) |
| SI (1) | SI3319611T1 (fr) |
| WO (1) | WO2017007836A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| HUE055668T2 (hu) | 2013-03-13 | 2021-12-28 | Sage Therapeutics Inc | Neuroaktív szteroidok |
| WO2015195967A1 (fr) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxystérols et leurs procédés d'utilisation |
| EP3166613A4 (fr) | 2014-07-09 | 2018-02-21 | Duke University | Compositions et méthodes pour la réparation de la myéline |
| MX2018000280A (es) | 2015-07-06 | 2018-03-08 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| SI3319611T1 (sl) | 2015-07-06 | 2021-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| WO2017173358A1 (fr) * | 2016-04-01 | 2017-10-05 | Sage Therapeutics, Inc. | Oxystérols et leurs méthodes d'utilisation |
| WO2017193046A1 (fr) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxystérols et méthodes d'utilisation associées |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| CN115850361A (zh) * | 2016-09-30 | 2023-03-28 | 萨奇治疗股份有限公司 | C7取代的氧固醇及其作为nmda调节剂的方法 |
| EP3529256B1 (fr) | 2016-10-18 | 2023-08-09 | Sage Therapeutics, Inc. | Oxystérols et leurs procédés d'utilisation |
| CN110267966B (zh) | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CA3050001A1 (fr) | 2017-01-13 | 2018-07-19 | Duke University | Compositions et methodes pour le traitement de maladies ou de troubles associes a la myeline et a une inflammation |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| KR20240035444A (ko) | 2021-06-11 | 2024-03-15 | 세이지 테라퓨틱스, 인크. | 알츠하이머병 치료를 위한 신경활성 스테로이드 |
| CN113667734B (zh) * | 2021-07-16 | 2022-05-24 | 四川大学华西医院 | Shank3片段序列甲基化检测试剂在制备精神分裂症诊断试剂盒中的用途 |
| WO2023028278A2 (fr) * | 2021-08-25 | 2023-03-02 | Sage Therapeutics, Inc. | Composés modulateurs de nmda positifs et leurs procédés d'utilisation |
| WO2023083979A1 (fr) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | STÉROÏDES 3β-HYDROXY, 3α-ÉTHYLE POUR LA MODULATION DU SOUS-TYPE α3 DU RÉCEPTEUR GABA-A |
| EP4447953A1 (fr) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| WO1995021617A1 (fr) | 1994-02-14 | 1995-08-17 | Cocensys, Inc. | Androstanes et pregnanes de modulation allosterique du recepteur du gaba |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| CZ394197A3 (cs) | 1995-06-06 | 1998-06-17 | Cocensys, Inc. | Neuroaktivní steroidy androstanové a pregnanové řady |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| US5841272A (en) | 1995-12-20 | 1998-11-24 | Sundstrand Corporation | Frequency-insensitive current sensor |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) * | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| US6376530B1 (en) * | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1450816A4 (fr) | 2001-11-08 | 2008-02-13 | Univ Chicago | Methode de traitement de troubles lies a un taux de cholesterol eleve |
| CA2468989A1 (fr) | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Traitement de la degenerescence maculaire liee au vieillissement |
| NZ547344A (en) | 2002-03-27 | 2007-11-30 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| GB0216621D0 (en) * | 2002-07-17 | 2002-08-28 | Imaging Res Solutions Ltd | Imaging compounds |
| AU2003291074A1 (en) * | 2002-11-22 | 2004-06-18 | Merck & Co., Inc. | 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as NR2B receptor antagonists |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| JP2009528291A (ja) | 2006-02-27 | 2009-08-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | オキシステロール化合物及びヘッジホッグ経路 |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| MX2010004682A (es) | 2007-11-06 | 2010-05-19 | Organon Nv | Metodo de supresion de hormonas en humanos. |
| WO2009090063A1 (fr) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Dérivés de sapogénine stéroïde, androstane et sapogénine triterpénoïde pour le traitement et la prévention de maladies infectieuses |
| BRPI0912362A2 (pt) | 2008-05-09 | 2015-10-06 | Univ Emory | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos |
| WO2010065709A2 (fr) | 2008-12-03 | 2010-06-10 | Amin Khan | Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088414A2 (fr) | 2009-01-28 | 2010-08-05 | Emory University | Potentialisateurs du récepteur nmda, sélectifs pour des sous-unités, et destinés au traitement d'états neurologiques |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| WO2011028794A2 (fr) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Traitement de la chorée de huntington avec de la cyclosérine et un agoniste des récepteurs nmda |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| GB201008047D0 (en) * | 2010-05-14 | 2010-06-30 | Ge Healthcare Ltd | Method of synthesis |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (fr) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combinaison d'un modulateur du récepteur hépatique x (lxr) et d'un modulateur du récepteur des œstrogènes (er) pour le traitement de maladies liées à l'âge |
| EP2714081A4 (fr) | 2011-05-27 | 2015-09-09 | Cytocure Llc | Méthodes, compositions et trousses pour le traitement du cancer |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| EP2841067A4 (fr) | 2012-04-25 | 2016-04-13 | Univ California | Plate-forme de criblage de médicaments pour le syndrome de rett |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| KR101993899B1 (ko) | 2012-12-18 | 2019-09-24 | 워싱톤 유니버시티 | 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법 |
| CN105073119A (zh) | 2013-01-23 | 2015-11-18 | 司菲埃拉制药私人有限公司 | 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物 |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| WO2014160441A1 (fr) | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, leurs compositions et utilisations |
| HUE055668T2 (hu) * | 2013-03-13 | 2021-12-28 | Sage Therapeutics Inc | Neuroaktív szteroidok |
| WO2015195967A1 (fr) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxystérols et leurs procédés d'utilisation |
| EP3166613A4 (fr) | 2014-07-09 | 2018-02-21 | Duke University | Compositions et méthodes pour la réparation de la myéline |
| US10016095B2 (en) * | 2014-10-03 | 2018-07-10 | Progressive International Corporation | Salad spinner |
| AU2015330906A1 (en) | 2014-10-07 | 2017-04-27 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| MX2018000280A (es) | 2015-07-06 | 2018-03-08 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| SI3319611T1 (sl) | 2015-07-06 | 2021-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| WO2018170336A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Formulation de nanoparticules lipidiques |
| IL271343B2 (en) | 2017-06-23 | 2023-12-01 | Intercept Pharmaceuticals Inc | Methods and intermediates for the preparation of bile acid derivatives |
| CN111565724A (zh) | 2017-11-10 | 2020-08-21 | 马瑞纳斯制药公司 | 加奈索酮用于治疗遗传性癫痫病 |
-
2016
- 2016-07-06 SI SI201631146T patent/SI3319611T1/sl unknown
- 2016-07-06 CN CN202110670292.XA patent/CN113292623A/zh active Pending
- 2016-07-06 BR BR122023021450-1A patent/BR122023021450A2/pt active Search and Examination
- 2016-07-06 DK DK16821924.4T patent/DK3319611T3/da active
- 2016-07-06 KR KR1020187003210A patent/KR102703602B1/ko active IP Right Grant
- 2016-07-06 EP EP21151891.5A patent/EP3828194A1/fr active Pending
- 2016-07-06 MD MDE20180512T patent/MD3319611T2/ro unknown
- 2016-07-06 IL IL256710A patent/IL256710B2/en unknown
- 2016-07-06 HU HUE16821924A patent/HUE053778T2/hu unknown
- 2016-07-06 US US15/742,425 patent/US10201550B2/en active Active
- 2016-07-06 ES ES16821924T patent/ES2865258T3/es active Active
- 2016-07-06 BR BR122021005552-1A patent/BR122021005552B1/pt active IP Right Grant
- 2016-07-06 LT LTEP16821924.4T patent/LT3319611T/lt unknown
- 2016-07-06 MA MA055097A patent/MA55097A/fr unknown
- 2016-07-06 PE PE2018000034A patent/PE20180483A1/es unknown
- 2016-07-06 CN CN201680051035.5A patent/CN108135912B/zh active Active
- 2016-07-06 IL IL305404A patent/IL305404A/en unknown
- 2016-07-06 WO PCT/US2016/041168 patent/WO2017007836A1/fr active Application Filing
- 2016-07-06 MX MX2018000282A patent/MX2018000282A/es active IP Right Grant
- 2016-07-06 PT PT168219244T patent/PT3319611T/pt unknown
- 2016-07-06 EP EP16821924.4A patent/EP3319611B1/fr active Active
- 2016-07-06 CA CA2991214A patent/CA2991214C/fr active Active
- 2016-07-06 RU RU2021100620A patent/RU2021100620A/ru unknown
- 2016-07-06 RU RU2018104278A patent/RU2744267C2/ru active
- 2016-07-06 KR KR1020247029533A patent/KR20240137111A/ko active Search and Examination
- 2016-07-06 MX MX2020011449A patent/MX2020011449A/es unknown
- 2016-07-06 BR BR112018000129-5A patent/BR112018000129B1/pt active IP Right Grant
- 2016-07-06 MA MA42410A patent/MA42410B1/fr unknown
- 2016-07-06 RS RS20210461A patent/RS61718B1/sr unknown
- 2016-07-06 PL PL16821924T patent/PL3319611T3/pl unknown
- 2016-07-06 JP JP2018500417A patent/JP2018519351A/ja not_active Withdrawn
- 2016-07-06 SG SG10202010553XA patent/SG10202010553XA/en unknown
- 2016-07-06 AU AU2016289967A patent/AU2016289967B2/en active Active
-
2018
- 2018-01-05 PH PH12018500065A patent/PH12018500065A1/en unknown
- 2018-01-24 CO CONC2018/0000660A patent/CO2018000660A2/es unknown
- 2018-12-20 US US16/227,099 patent/US10765685B2/en active Active
-
2020
- 2020-07-29 US US16/942,245 patent/US20210145848A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021002172A patent/JP2021054864A/ja not_active Withdrawn
- 2021-03-31 HR HRP20210526TT patent/HRP20210526T8/hr unknown
- 2021-04-13 CY CY20211100316T patent/CY1124496T1/el unknown
- 2021-08-20 AU AU2021218228A patent/AU2021218228B2/en active Active
-
2022
- 2022-06-08 JP JP2022093073A patent/JP2022120062A/ja active Pending
-
2024
- 2024-01-16 AU AU2024200268A patent/AU2024200268A1/en active Pending
- 2024-03-13 US US18/603,816 patent/US20240277733A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA40069A (fr) | Molécules de liaison trispécifiques et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
| MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| MA41999A (fr) | Compositions d'acide obéticholique et procédés d'utilisation | |
| MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation | |
| MA42979A (fr) | Anticorps anti-age et procédés d'utilisation correspondants | |
| MA41558A (fr) | Compositions d'allergènes mélangés et leurs procédés d'utilisation | |
| MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |